Mazdutide Research

PeptidePrices

Research summary

StatusNot FDA-approved (Phase III)NCAANot listed

Cited sources: 3
Clinical sources: 1
Review layer: Curated

Evidence at a glance

What the research says about Mazdutide

The Mazdutide evidence base cited here is 3 sources — 1 clinical. Its strongest evidence is human — a clinical study, most recently 2025 ("GLORY-1 / GLORY-2 Phase 3 Topline (company-reported — VERIFY against pri…"). Regulatory status: Not FDA-approved (Phase III).

Summary

Key takeaways

Mazdutide (IBI362 / LY3305677) is a dual GLP-1 + glucagon receptor agonist — an oxyntomodulin analog. It's a different dual-agonist than GLP-2T (which is GLP-1/GIP): mazdutide pairs GLP-1 appetite suppression with glucagon-driven thermogenesis and hepatic fat metabolism.
Mechanistically it fills the GLP-1/glucagon slot in the incretin landscape (GLP-1S = GLP-1; GLP-2T = GLP-1/GIP; GLP-3R = triple agonist; survodutide = also GLP-1/glucagon).
It is not FDA-approved and is developed by Innovent/Lilly, with most trials run in Chinese populations.

Overview

It is not FDA-approved, and several of the figures below are company-reported/topline — flagged where that's the case. Everything here is research context, not medical guidance.

What Is Mazdutide?

Its defining feature is the receptor pair: GLP-1 + glucagon. That makes it the dual-agonist sibling of survodutide, and a contrast to GLP-2T's GLP-1/GIP pairing.

How It Works

GLP-1 arm

Stimulates glucose-dependent insulin secretion, suppresses glucagon between meals, slows gastric emptying, and reduces appetite via the hypothalamus — the same appetite/glycemic machinery as GLP-1S.

Glucagon arm

Increases energy expenditure/thermogenesis and improves hepatic fat metabolism — the lever that single GLP-1 drugs lack. Glucagon alone would raise blood sugar, but the simultaneous GLP-1 activity offsets that, so the net effect is weight loss plus glycemic control.

Reported Results (topline — verify)

DREAMS-3 (head-to-head vs GLP-1S, T2D + obesity, 32 wk): reported more patients hitting combined HbA1c <7% AND ≥10% weight loss — company/topline.
Metabolic markers reported to improve (waist, blood pressure, triglycerides).

All GLORY/DREAMS figures here are company-reported/topline and 2025-dated from largely Chinese cohorts. Confirm against the primary peer-reviewed publications before citing as established.

Side Effects & Safety

Legal & Status

Mazdutide is investigational and not FDA-approved. It is developed by Innovent/Eli Lilly (trials largely in Chinese populations) and is sold by research-chemical suppliers for laboratory use only, not intended for human consumption.

Citations

3 peer-reviewed sources

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.